Mohammed Khoso Baluch is Senior Vice President and President of the Europe region of UCB, a global biopharmaceutical company. Mr. Khoso Baluch became the CEO and a member of the Board of Directors of CorMedix, a company listed in the US, in October 2016. Before joining UCB, Mohammed Khoso Baluch worked for Eli Lilly & Co. for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Mohammed Khoso Baluch also served as Vice President of the US Diabetes and Family Health Business Unit during his tenure at Lilly. Mr. Baluch also served as a member of the board of the Juvenile Diabetes Research Foundation, Indiana Chapter and Chairman of the Nominations Committee. Finally, Mohammed Khoso Baluch served on the American Diabetes Association National Industry Advisory Board. He is currently a member of the Executive Committee of the World Federation of Advertisers (FMA).

Pascale Boissel is a consultant in finance and restructuring operations, a field in which she has 25 years of experience. Pascale Boissel is the part-time CFO of Novadiscovery, a biotech company which develops models and simulations in order to avoid the risks in developing new drugs. Before that, she was previously the Deputy-Chief Executive Officer and Head of Finance and Administration of the BIOASTER institute, a French not-for-profit organization that develops collaborative research programs in the field of infectious diseases and microbiology. In 2009, Madame Boissel joined biotech company Ipsogen in the United States and was responsible for financing activities. She played a major role in the transaction which led to completion of the acquisition of Ipsogen in 2011. Before joining Ipsogen, she worked for listed French companies, as Deputy Chief Financial Officer, in the sector of transactions and commercial control. Pascale Boissel began her career in audit and corporate finance at PricewaterhouseCoopers. She has significant experience in international accounting practices.

Rich Kender has served as a member of the Company's board of directors since 2015. Mr. Kender joined Merck & Co., Inc. in 1978, and served as Merck’s Vice President of Corporate Development from 1996 to 2000. In 2000, he was promoted to Senior Vice President and his responsibilities were expanded to include Corporate Licensing and Worldwide Business Development, where he managed Merck’s Mergers and Acquisitions, Licensing, Financial Evaluation and Analysis and Global Competitive Intelligence departments. Mr. Kender retired from Merck in September 2013. Mr. Kender currently serves on the board of directors and audit committee of Seres Therapeutics and on the board of directors of Abide Therapeutics. He holds a BS in Accounting from Villanova University and an MBA from Fairleigh Dickinson University.

Thomas Kuhn began his career with Merck KGaA in 2000 where he held various positions in clinical development, mainly in the therapeutic area of Type 2 diabetes and was responsible, in particular, for forging partnerships with Japanese pharmaceutical companies. Between 2004 and 2007, he directed Merck’s global R&D projects with two products in Phase 2 clinical trials and all the life cycle management projects primarily for Glucophage®, the current reference in diabetes treatment. Following Merck’s acquisition of Serono in 2007, Thomas Kuhn was part of the team which refined Merck Serono’s strategy for divesting from the diabetes therapeutic area. Thomas Kuhn initiated and concluded the project for the transfer of Merck Serono’s assets under development in Diabetes to a new legal entity called Poxel. Since this transfer, Thomas Kuhn has been Poxel’s Chief Executive Officer. Mr. Kuhn holds a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge Business School (UK) of Medicine.